Jefferies Maintains a 'Buy' on Amarin (AMRN); Concern Over NCE Delay And Meta-analysis Presents A Buying Opportunity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Streetinsider.com's Hot Lunchtime Reads 09/11: (AMRN) (UPS) (LVS) (S) (M) (LRN)
September 11, 2012 12:18 PM EDTThe following is a list of notable articles to help get you through the lunch hour:Against the Grain: Burberry's Fall = Success for Other Retailers (M) (GPS) (JCP) ->... More
Amarin (AMRN) NCE Delay Could Be Related to Patents
September 11, 2012 10:37 AM EDTMKM Partners commented on Amarin Corporation (NASDAQ: AMRN) Tuesday following another NCE decision delay on Vascepa.
Analyst Jon LeCroy, M.D. said he continues to believe the delay is a mild... More
Pre-Open Movers 9/11: (WSM) (SNSS) (CASY) Higher; (NAVB) (PPO) (SQNM) Lower (more...)
September 11, 2012 9:31 AM EDTWSB Holdings, Inc.(NASDAQ: WSB) 91% HIGHER ; acquired by Old Line Bancshares (NASDAQ: OLBK).
Sunesis Pharma (NASDAQ: SNSS) 47% HIGHER ; to Boost Sample Size in Phase 3 VALOR of Vosaroxin in AML
Navidea Biopharmaceuticals, Inc (NASDAQ:... More
Canaccord Genuity Reiterates a 'Buy' on Amarin Corporation (AMRN); Positive View on Vascepa
September 11, 2012 8:18 AM EDTCanaccord Genuity reiterates a 'Buy' on Amarin Corporation (NASDAQ: AMRN) price target of $26.00.
Analyst, Ritu Baral, said, "Reiterate rating and price target; maintain positive view on Vascepa approval and commercial, partnering potential. We continue to expect BD talks to intensify and Vascepa to... More
Amarin Corp (AMRN) Pressured Early as Vascepa Orange Book Decision Delayed...Again
September 11, 2012 8:15 AM EDTShares of Amarin Corp Plc (Nasdaq: AMRN) are getting hit Tuesday morning following a late-Monday disclosure for Vascepa.
According to the filing, Amarin... More
After-Hours Movers 9/10: (CASY) (GMCR) Higher; (NAVB) (PANW) (SQNM) Lower (more...)
September 10, 2012 5:51 PM EDTNavidea Biopharmaceuticals, Inc (NASDAQ: NAVB) 35% LOWER ; The FDA does not approve Lymphoseek, co. receives CRL.
Voyager Oil & Gas, (AMEX: EOX) 12% LOWER ; commenced... More
Amarin (AMRN) Said No FDA NCE Decision in August Orange Book
September 10, 2012 5:10 PM EDTAmarin Corp Plc (NASDAQ: AMRN) said after the close of trading Monday that it does not expect an FDA NCE decision by the next Orange Book, due on our about September 14, 2012.
From the filing:
Typically, the U.S. Food and Drug Administration (FDA) publishes a determination on the... More
